Advanced search×

The impact of diabetes on prescription drug costs: the population-based Turin study.

Diabetologia 51(5):795-801 (2008) PMID 18317724

The aim of our study was to compare prescription drug costs in diabetic and non-diabetic individuals in a large population-based Italian cohort covered by the National Health System.

DOI: 10.1007/s00125-008-0957-4
Version: za2963e q8zad q8zba q8zc1 q8zd9 q8ze9 q8zfb q8zg9

Similar articles you may find interesting…

  1. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related dia...

    Audio, Transactions of the IRE Professio... 32(10):1783-8 (2009) PMID 19592632

    Insulin therapy safely reversed chronic weight loss in patients with CFRD FH-....
  2. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-ob...

    Eur J Endocrinol 158(1):35-46 (2008) PMID 18166815

    In non-obese T2DM patients, metformin reduced postprandial levels of glycaemia, triglycerides and FFA similarly compared to the prandial insulin secretagogue, repaglinide. Furthermore, metformin reduced fasting and postprandial cholesterolaemia and insulinaemia compared with repaglinide. These data...
  3. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled...

    Atherosclerosis 211(2):9 (2010) PMID 20594555

    We found no evidence for a statistically significant effect of rosiglitazone on SVG atherosclerosis whereas significant effects on glycemic control and on the cardiometabolic risk profile appeared to be modulated in part by changes in subcutaneous adiposity. Copyright 2010 Elsevier Ireland Ltd. All...